-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
-
Summary
-
Biomarin Pharmaceutical Inc quarterly/annual Amortization of Intangible Assets history and growth rate from 2011 to Q3 2025.
- Biomarin Pharmaceutical Inc Amortization of Intangible Assets for the quarter ending September 30, 2025 was $4.85M, a 3.23% decline year-over-year.
- Biomarin Pharmaceutical Inc Amortization of Intangible Assets for the twelve months ending September 30, 2025 was $24.2M, a 50.5% decline year-over-year.
- Biomarin Pharmaceutical Inc annual Amortization of Intangible Assets for 2024 was $43.3M, a 30.5% decline from 2023.
- Biomarin Pharmaceutical Inc annual Amortization of Intangible Assets for 2023 was $62.2M, a 7.41% decline from 2022.
- Biomarin Pharmaceutical Inc annual Amortization of Intangible Assets for 2022 was $67.2M.
Amortization of Intangible Assets, Trailing 12 Months (USD)
Amortization of Intangible Assets, Quarterly (USD)
Amortization of Intangible Assets, YoY Quarterly Growth (%)
Amortization of Intangible Assets, Annual (USD)
Amortization of Intangible Assets, YoY Annual Growth (%)